Skip to main content

Clinical Biochemistry, Drug Delivery & Therapy

The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.

With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.

In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.

Team

Roser Ferrer  Costa

Roser Ferrer Costa

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Ibane Abasolo Olaortua

Ibane Abasolo Olaortua

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Joan López Hellin

Joan López Hellin

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Simon Schwartz Navarro

Simon Schwartz Navarro

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Diana Fernandes de Rafael

Diana Fernandes de Rafael

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria del Pilar Reimundo Diaz-Fierros

Maria del Pilar Reimundo Diaz-Fierros

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Roser Ferrer  Costa

Roser Ferrer Costa

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Ibane Abasolo Olaortua

Ibane Abasolo Olaortua

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Joan López Hellin

Joan López Hellin

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Simon Schwartz Navarro

Simon Schwartz Navarro

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Diana Fernandes de Rafael

Diana Fernandes de Rafael

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria del Pilar Reimundo Diaz-Fierros

Maria del Pilar Reimundo Diaz-Fierros

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Research lines

Anàlisi de dades massives (big data), explotació de dades i mostres als Laboratoris Clínics

IP: Roser Ferrer Costa

Desenvolupament de models animals per l'avaluació ràpida i eficient de tractaments nanotecnològics

IP: Zamira Vanessa Diaz Riascos

Desenvolupament i optimització de mètodes diagnòstics

IP: Joan López Hellin

Diagnosis, prognosis i monitoratge de malalties minoritàries, especialment malalties metabòliques

IP: Clara Carnicer Cáceres

Projects

(Standard-D) Standardization of HDV-RNA quantification: a need that can no longer be ignored.

IP: Francisco Rodríguez Frias
Collaborators: David Tabernero Caellas
Funding agency: GILEAD SCIENCES SLU
Funding: 49961.71
Reference: GLD22/00080
Duration: 28/02/2023 - 27/02/2025

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino , Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Francesc Martínez Trucharte, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 31/12/2024

Personal Técnico de Apoyo 2021

IP: Ibane Abasolo Olaortua
Collaborators: Diana Fernandes de Rafael, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 42600
Reference: PTA2021-021005-I
Duration: 01/01/2023 - 31/12/2025

Ministerio de Ciencia

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

Blog

News

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.